Research Article
Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations
Table 1
Baseline characteristics of 45 patients with EGFR double mutations.
| | Characteristics | Total
(%) | 19Del + L858R
(%) | 19Del + T790M
(%) | L858R + T790M
(%) | | |
| | Gender | | | | | 8.46 | 0.0145 | | Male | 22 (48.9%) | 13 (76.5%) | 5 (35.7%) | 4 (28.6%) | | | | Female | 23 (51.1%) | 4 (23.5%) | 9 (64.3%) | 10 (71.4%) | | | | Age (years) | | | | | 3.23 | 0.1986 | | <60 | 26 (57.8%) | 7 (41.2%) | 10 (71.4%) | 9 (64.3%) | | | | ≥60 | 19 (42.2%) | 10 (58.8%) | 4 (28.6%) | 5 (35.7%) | | | | Smoking | | | | | 2.70 | 0.2588 | | Yes | 13 (28.9%) | 7 (41.2%) | 2 (14.3%) | 4 (28.6%) | | | | No | 32 (71.1%) | 10 (58.8%) | 12 (85.7%) | 10 (71.4%) | | | | Clinical stage | | | | | 2.38 | 0.3048 | | I-II | 13 (28.9%) | 3 (17.6%) | 6 (42.9%) | 4 (28.6%) | | | | III-IV | 32 (71.1%) | 14 (82.4%) | 8 (57.1%) | 10 (71.4%) | | | | ECOG PS | | | | | 1.18 | 0.5539 | | 0-1 | 40 (88.9%) | 14 (82.4%) | 13 (92.9%) | 13 (92.9%) | | | | 2 | 5 (11.1%) | 3 (17.6%) | 1 (7.1%) | 1 (7.1%) | | | | EGFR-TKIs | | | | | 2.71 | 0.2578 | | Yes | 24 (53.3%) | 11 (64.7%) | 8 (57.1%) | 5 (35.7%) | | | | No | 21 (46.7%) | 6 (35.3%) | 6 (42.9%) | 9 (64.3%) | | | | Pathology | | | | | 0.97 | 0.6145 | | Adenocarcinoma | 43 (95.6%) | 16 (94.1%) | 13 (92.9%) | 14 (100%) | | | | Squamous carcinoma | 2 (4.4%) | 1 (5.9%) | 1 (7.1%) | 0 (0%) | | |
|
|
